ReviewCureus2026
Irisin in Pediatric Obesity: A Narrative Review of Current Evidence.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity in children and adolescents represents an escalating global health challenge associated with chronic low-grade inflammation and dysregulation of myokine and adipokine secretion. Irisin, encoded by the FNDC5 gene, plays a pivotal role in energy homeostasis by promoting the "browning" of white adipose tissue (WAT) and increasing energy expenditure through thermogenesis. The aim of this study was to establish the diagnostic and therapeutic significance of irisin in the context of childhood obesity and to assess its usefulness as a marker for the early detection and monitoring of metabolic disorders. A comprehensive literature search was conducted using the PubMed database. Findings were limited to studies published within the last five years, from April 14, 2021, to April 14, 2026. Only studies in English were included. We used the following keywords and phrases: irisin; FNDC5; obesity; child; children; pediatric; adolescence; adolescent. Twenty studies met the inclusion criteria and were included in this narrative review. Studies confirmed that serum irisin concentration typically correlates positively with BMI and leptin levels, which may be described as a compensatory mechanism for improving insulin sensitivity. In obese adolescent girls with polycystic ovary syndrome (PCOS), irisin levels are lower but increase with a reduction in fat mass. High-intensity interval training (HIIT) stimulates higher irisin release than moderate-intensity training. In rarer conditions, such as Prader-Willi syndrome (PWS), irisin levels are reduced, which is associated with impaired bone metabolism and decreased muscle mass. Irisin can also act as a marker of hepatic steatosis and as a factor supporting executive functions in overweight children. Irisin represents a promising and sensitive biomarker of metabolic status and adipose tissue content in pediatric patients. Its monitoring may allow for a clear assessment of therapeutic effectiveness and dynamic changes in the child's metabolic profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.